A Phase 2 interventional study of Aspirin 81Mg Ec Tab in Preeclampsia Postpartum, sponsored by MemorialCare Health System. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by MemorialCare Health System · Phase 2, Interventional, and Treatment
The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.
Preeclampsia is a condition of the antenatal and postpartum periods, which manifests as new-onset hypertension and end-organ damage. Globally, preeclampsia is estimated to affect up to 9% of all pregnancies, though as many as two-thirds of patients who receive this diagnosis will remain hypertensive beyond the time of their postpartum hospital discharge. Because of this, postpartum preeclampsia is the leading cause of postpartum hospital readmission in the United States. Anti-hypertensive medications and magnesium sulfate are temporizing therapies aimed at preventing the immediate sequelae of preeclampsia such as seizures, stroke, and end-organ damage. However, there are no therapies directly targeting the pathophysiology underlying postpartum preeclampsia, which poses difficulties in promoting blood pressure recovery to a normotensive state.
Preeclampsia is considered a disorder of abnormal placentation, leading to the release of abnormal pro-angiogenic, anti-angiogenic, and vasoactive molecules. Specifically, excess elevations in anti-angiogenic proteins like soluble fms-like tyrosine kinase 1 (sFlt-1) relative to pro-angiogenic proteins like placental growth factor (PlGF) are thought to cause vasospasm and, in turn, hypertension. As such, it seems plausible that persistent postpartum sFlt-1 elevation is implicated in the pathophysiology of postpartum preeclampsia.
At low doses, acetylsalicylic acid, or aspirin, has been proven to target the aforementioned angiogenic imbalance by decreasing serum sFlt-1 levels. While aspirin is widely used during pregnancy to mitigate the risk of preeclampsia, the utility of aspirin in the postpartum period to target these pathways and promote BP recovery to a normotensive state is unknown. The central hypothesis of this trial is that use of aspirin in the first week postpartum will enhance recovery from preeclampsia by improving blood pressure recovery via decreased levels of sFlt-1.
Exclusion Criteria:
Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery
Drug: Aspirin 81Mg Ec Tab
Standardized postpartum blood pressure control
Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Reduction in sFlt-1
This outcome will determine the absolute change in sFlt-1, an anti-angiogenic protein implicated in the pathophysiology of preeclampsia.
Time frame: 1 week postpartum
Normotension (ACOG)
This outcome will measure the proportion of patients who achieve a blood pressure of \<140/90, as defined by ACOG, without any further elevated values.
Time frame: 1 week postpartum
Normotension (JNC)
This outcome will measure the proportion of patients who achieve a blood pressure of \<130/80, as defined by JNC, without any further elevated values.
Time frame: 1 week postpartum
Time to normotension
This outcome will assess the length of time in days to normotension after randomization. Normotension will be defined by both ACOG and JNC criteria.
Time frame: 6 weeks postpartum
Anti-hypertensive therapy
This outcome will assess if additional or increased doses of anti-hypertensive therapies are needed following randomization.
Time frame: 6 weeks postpartum
Readmission
This outcome will assess if a study participant is readmitted for blood pressure or preeclampsia related reasons following randomization.
Time frame: 6 weeks postpartum
Adherence
This outcome will assess for adherence to aspirin therapy in those randomized to the aspirin arm. This is defined as greater than 90% consumption of the prescribed doses.
Time frame: 1 week postpartum
Enrollment feasibility
This outcome will assess feasibility for future studies, defined as both the number of patients randomized by the number of patients eligible and the number of patients who completed the study protocol divided by the number of patients randomized.
Time frame: 1 week postpartum
Postpartum hemorrhage
This safety outcome is defined as a postpartum hemorrhage of greater than 1 liter following randomization.
Time frame: 6 weeks postpartum
Postpartum bleeding requiring intervention
This safety outcome is defined as postpartum bleeding requiring intervention (uterotonic administration, intrauterine balloon placement, dilation and curettage, or uterine artery embolization) following randomization.
Time frame: 6 weeks postpartum
Unplanned postpartum evaluation for bleeding
This safety outcome is defined as the need for urgent evaluation for bleeding in the clinic/office, obstetrical triage unit, or emergency room for vaginal bleeding.
Time frame: 6 weeks postpartum
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MemorialCare Health System